程序性细胞死亡
葛兰素史克-3
GSK3B公司
神经纤维缠结
高磷酸化
纠纷
老年斑
淀粉样蛋白(真菌学)
激酶
神经科学
转基因小鼠
内嗅皮质
医学
生物
转基因
糖原合酶
阿尔茨海默病
τ蛋白
海马结构
细胞生物学
淀粉样前体蛋白
细胞凋亡
体内
磷酸化
病理
生物化学
纯数学
数学
生物技术
疾病
基因
作者
L. Serenó,Mireia Coma,M. Rodríguez,P. Sánchez-Ferrer,María‐Belén Sánchez‐Saudinós,Ignasi J. Gich,Jose Manuel Agullo,Mar Pérez,Jesús Ávila,Cristina Guardia‐Laguarta,Jordi Clarimón,Alberto Lleó,Teresa Gómez‐Isla
标识
DOI:10.1016/j.nbd.2009.05.025
摘要
Amyloid deposits, neurofibrillary tangles, and neuronal cell death in selectively vulnerable brain regions are the chief hallmarks in Alzheimer's (AD) brains. Glycogen synthase kinase-3 (GSK-3) is one of the key kinases required for AD-type abnormal hyperphosphorylation of tau, which is believed to be a critical event in neurofibrillary tangle formation. GSK-3 has also been recently implicated in amyloid precursor protein (APP) processing/Aβ production, apoptotic cell death, and learning and memory. Thus, GSK-3 inhibition represents a very attractive drug target in AD and other neurodegenerative disorders. To investigate whether GSK-3 inhibition can reduce amyloid and tau pathologies, neuronal cell death and memory deficits in vivo, double transgenic mice coexpressing human mutant APP and tau were treated with a novel non-ATP competitive GSK-3β inhibitor, NP12. Treatment with this thiadiazolidinone compound resulted in lower levels of tau phosphorylation, decreased amyloid deposition and plaque-associated astrocytic proliferation, protection of neurons in the entorhinal cortex and CA1 hippocampal subfield against cell death, and prevention of memory deficits in this transgenic mouse model. These results show that this novel GSK-3 inhibitor has a dual impact on amyloid and tau alterations and, perhaps even more important, on neuronal survival in vivo further suggesting that GSK-3 is a relevant therapeutic target in AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI